There is a coenzyme inside every cell in your body right now doing work you are not aware of. It is helping convert the food you ate this morning into usable energy. It is activating the proteins that repair your DNA after UV exposure. It is fueling the sirtuins — a family of enzymes your body uses to regulate inflammation, circadian rhythm, and metabolic efficiency. Without it, none of those processes run correctly.
That coenzyme is NAD+ — nicotinamide adenine dinucleotide — and by the time most people are reading an article like this, they have already lost between 40 and 60% of the levels they had at 20.
This is not a fringe finding. It has been replicated across dozens of peer-reviewed studies over the past two decades. The question is not whether NAD+ declines. It does, predictably, starting in your 30s and accelerating through your 40s and 50s. The questions that actually matter are: what does that decline feel like in practice, what does restoring it actually accomplish, and — critically — how you restore it in a way that reaches the cells that need it.
What NAD+ Actually Does
The term "cellular energy" gets used loosely in wellness marketing to mean almost anything. In the context of NAD+, it means something specific: NAD+ is the primary electron carrier in the mitochondrial electron transport chain. Without adequate NAD+, your mitochondria cannot efficiently run oxidative phosphorylation — the process by which your cells produce ATP, the currency of all cellular work.
Beyond energy production, NAD+ is the required substrate for three classes of enzymes that have become central to longevity research:
The practical consequence of all this is that NAD+ decline does not announce itself as a single symptom. It shows up as a cluster of things that feel like ordinary aging: slower recovery from exercise, reduced mental clarity in the afternoon, disrupted sleep architecture, increased susceptibility to inflammation, and a general sense that the body is less efficient than it used to be.
The Supplement Industry's Delivery Problem
Here is the thing that most NAD+ supplement marketing carefully avoids explaining: NAD+ itself is not well-absorbed orally. The molecule does not cross the intestinal wall in meaningful quantities. What you are actually buying when you purchase an "NAD+ supplement" is typically a precursor — NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) — which your body then converts into NAD+ through a multi-step enzymatic pathway.
This is not a scam. The precursor pathway is real. NMN and NR do raise systemic NAD+ levels in clinical studies — particularly at higher doses and with consistent use over weeks. But the conversion is not guaranteed, not uniform across individuals, and not efficient in people with mitochondrial dysfunction or chronic inflammation (precisely the population most likely to benefit from NAD+ restoration).
"The cells that most need NAD+ are often the same cells least capable of efficiently running the conversion pathway from oral precursors."
The more significant issue is bioavailability in target tissues. Muscle cells, neurons, and cardiac tissue — the three tissue types most affected by NAD+ depletion — are also the tissues where conversion efficiency of oral precursors is most variable. The cells that most need NAD+ are often the same cells least capable of efficiently running the conversion pathway.
Subcutaneous Restoration: Why Delivery Matters
Subcutaneous NAD+ administration bypasses the gut and the hepatic first-pass metabolism that degrades a significant portion of orally ingested compounds. The molecule enters systemic circulation directly, achieving peak plasma concentrations that oral dosing rarely matches at commercially available doses.
The comparison is not subtle:
| Variable | Oral NMN/NR Supplements | Subcutaneous NAD+ |
|---|---|---|
| Primary mechanism | Precursor conversion (enzymatic) | Direct systemic delivery |
| Bioavailability variability | High — depends on gut health, enzymatic capacity, inflammation status | Low — bypasses conversion pathway entirely |
| Time to effect | Weeks of consistent dosing for meaningful tissue elevation | 48–72 hours in most protocols |
| Dose precision | Difficult — conversion rate unknown | Exact — physician-calibrated per protocol |
| Physician oversight | None (OTC) | Required — protocol reviewed and adjusted |
| Compounding standard | Varies — supplement GMP, not pharmaceutical grade | 503B cGMP facility, lot-tested |
The distinction in practice: most people who switch from long-term oral NMN supplementation to a physician-supervised subcutaneous protocol report a qualitative difference within the first week. Not universally — individual response varies — but the pattern is consistent enough that it has become one of the more frequently cited experiences in Foundry member intake reviews.
Intravenous NAD+ infusions are offered at many longevity clinics and produce rapid, measurable elevation in plasma NAD+. They are also expensive ($400–$800 per session), time-intensive (infusions take 2–4 hours to minimize the flushing response), and inconvenient as a regular protocol. Subcutaneous administration achieves comparable tissue elevation over a slightly longer time horizon — with the significant advantage of being self-administered at home on a physician-designed schedule.
What Restoration Actually Feels Like
The research literature on NAD+ restoration in humans describes outcomes across several domains: improved cognitive function, better sleep architecture (particularly deeper slow-wave sleep), improved metabolic markers including insulin sensitivity, and reduced inflammatory biomarkers in protocols running 12 weeks or longer.
In practice, the effects most consistently reported in the first two to four weeks of subcutaneous NAD+ are more immediate and less abstract: clearer thinking in the afternoon window (roughly 2–4pm), improved recovery from both exercise and poor sleep, and a reduction in what many members describe as cognitive friction — the sense of effortful thinking that accumulates as a workday extends.
The longer-term effects — the metabolic and inflammatory changes the research documents — require time and consistency. NAD+ is not a stimulant. It is a substrate. What it restores is the infrastructure that your cells use to do their work. The effect of restoring that infrastructure is not dramatic in the way that a stimulant is. It is more like the difference between a machine running at 60% capacity and the same machine running at 90%.
The Foundry RX NAD+ Protocol
Foundry RX offers physician-supervised subcutaneous NAD+ through the Foundry Club membership. All compounds are sourced from US-registered raw material suppliers and compounded at a 503B-registered outsourcing facility under cGMP standards — the same pharmaceutical-grade compounding used for hospital outsourcing, not consumer supplement manufacturing.
Your protocol is built by a licensed US provider who reviews your intake, health history, and goals. Dosing is calibrated individually — there is no one-size protocol for NAD+ restoration, because the appropriate starting dose and titration schedule depend on your current health status, existing supplementation, and specific goals.
Most members are shipping within 48 hours of approval. The protocol includes monthly provider check-ins to adjust as your response develops.
NAD+ and 30+ physician-supervised protocols.
503B compounded. US sourced. Delivered to all 50 states.
Stacking NAD+ with Other Protocols
NAD+ is frequently paired with Sermorelin (a growth hormone secretagogue) and NMN for what longevity practitioners call a cellular optimization stack. The rationale: Sermorelin restores natural GH pulsatility, which supports mitochondrial biogenesis; NAD+ provides the substrate those mitochondria need to run efficiently; NMN extends the systemic NAD+ elevation between subcutaneous doses.
For members pursuing GLP-1 protocols, NAD+ co-therapy is particularly relevant. GLP-1 agonists like Semaglutide and Tirzepatide drive significant metabolic changes — and the metabolic machinery that adapts to those changes runs on NAD+. A protocol that supports metabolic flexibility at the cellular level tends to produce better outcomes on GLP-1 than one that does not.
These are conversations that happen at the provider level, not at checkout. Your Foundry physician reviews your full protocol picture before making any recommendation to stack. The goal is optimization, not complexity.